Key result
Mesenchymal stem cell therapy modulates extracellular matrix remodeling and reduces post-MI fibrosis.
Mesenchymal stem cell therapy shows potential for cardiac regeneration and modulating extracellular matrix remodeling to improve diastolic dysfunction after myocardial infarction, though long-term safety requires further study.
Answers are grounded in this paper and cite their sources.
Should not yet change post-MI care; leaves open long-term diastolic benefits and need for prospective trials.
The decline in cardiac contractility due to damage or loss of cardiomyocytes is intensified by changes in the extracellular matrix leading to heart remodeling. An excessive matrix response in the ischemic cardiomyopathy may contribute to the elevated fibrotic compartment and diastolic dysfunction. Fibroproliferation is a defense response aimed at quickly closing the damaged area and maintaining tissue integrity. Balance in this process is of paramount importance, as the reduced post-infarction response causes scar thinning and more pronounced left ventricular remodeling, while excessive fibrosis leads to impairment of heart function. Under normal conditions, migration of progenitor cells to the lesion site occurs. These cells have the potential to differentiate into myocytes in vitro, but the changed micro-environment in the heart after infarction does not allow such differentiation. Stem cell transplantation affects the extracellular matrix remodeling and thus may facilitate the improvement of left ventricular function. Studies show that mesenchymal stem cell therapy after infarct reduces fibrosis. However, the authors did not specify whether they meant the reduction of scarring as a result of regeneration or changes in the matrix. Research is also necessary to rule out long-term negative effects of post-acute infarct stem cell therapy.
No takes yet. Share an insight, caveat, or question.
Piątek et al. (2022) conducted a review in Myocardial Infarction and Diastolic Dysfunction. Mesenchymal Stem Cell Therapy was evaluated. Mesenchymal stem cell therapy after myocardial infarction modulates extracellular matrix remodeling and reduces fibrosis, though its long-term effects on diastolic function require further investigation.
Synapse has enriched 10 related papers. Consider them for comparative context: